Teva’s CGRP-Inhibitor Reduced Monthly Migraine Days in Late-Stage Trial

Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.